Pharsight

Drugs that contain Cenobamate

1. Xcopri patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7598279 SK LIFE Neurotherapeutic azole compounds
Oct, 2032

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11654133 SK LIFE Use of [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate in combination therapy
Jun, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Mar 10, 2025

NCE-1 date: 2024-03-10

Market Authorisation Date: 10 March, 2020

Treatment: Co-administration of cenobamate with phenobarbital and/or phenytoin for the treatment of partial onset seizures

Dosage: TABLET;ORAL

More Information on Dosage

XCOPRI family patents

Family Patents